Patents by Inventor Mark Rogers-Evans

Mark Rogers-Evans has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20070027163
    Abstract: The present invention relates to indol-3-yl-carbonyl-piperidin and piperazin derivatives which act as V1a receptor antagonists and which are represented by Formula I: wherein the residues R1 to R3 are as defined herein. The invention also relates to pharmaceutical compositions containing such compounds, and methods for preparation of the compounds and compositions. The invention further relates to methods for treating dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder, anxiety and depressive disorders.
    Type: Application
    Filed: July 25, 2006
    Publication date: February 1, 2007
    Inventors: Caterina Bissantz, Christophe Grundschober, Hasane Ratni, Mark Rogers-Evans, Patrick Schnider
  • Publication number: 20070027173
    Abstract: The invention relates to indol-3-yl-carbonyl-spiro-piperidine derivatives which act as V1a receptor antagonists and which are represented by Formula I: wherein the spiro-piperidine head group A and the residues R1, R2 and R3 are as defined herein. The invention further relates to pharmaceutical compositions containing such compounds, methods for preparing the compounds and pharmaceutical compositions, and their use in the treatment of dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder, anxious and depressive disorders.
    Type: Application
    Filed: July 10, 2006
    Publication date: February 1, 2007
    Inventors: Caterina Bissantz, Christophe Grundschober, Hasane Ratni, Mark Rogers-Evans, Patrick Schnider
  • Publication number: 20070021463
    Abstract: The present invention relates to Indol-3-yl-carbonyl-piperidin-benzoimidazol derivatives which act as V1a receptor antagonists and which are represented by Formula I: wherein the residues R1 to R7 are as defined herein. The invention further relates to pharmaceutical compositions containing such compounds, their use in treating dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephritic syndrome, obsessive compulsive disorder, anxiety and depressive disorders, and methods of preparation thereof.
    Type: Application
    Filed: July 20, 2006
    Publication date: January 25, 2007
    Inventors: Caterina Bissantz, Christophe Grundschober, Hasane Ratni, Mark Rogers-Evans, Patrick Schnider
  • Patent number: 7011960
    Abstract: The present invention relates to a new process for the preparation compounds of formula I wherein R1, R2, R3 and n are as described in the description which process comprises reacting compounds of formula II wherein R1, R2, R3, n and R4 are as described in the description, with a protease in an aqueous system containing an organic co-solvent. The compound of formula I are useful for the preparation of 1,5-benzothiazepines which are useful as enzyme inhibitors, such as protease, interleukin-1?-converting enzyme, elastase or angiotensin converting enzyme, GPCR antagonists (cholecystokinin, angiotensin II receptor).
    Type: Grant
    Filed: September 23, 2002
    Date of Patent: March 14, 2006
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Konrad Bleicher, Scott Borthwick, Hans Iding, Mark Rogers-Evans, Stefan Schmid, Han Min Tong, Beat Wirz
  • Publication number: 20050143373
    Abstract: The present invention relates to compounds of the general formula and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases such as obesity by selective modulation of CB1 receptors.
    Type: Application
    Filed: February 22, 2005
    Publication date: June 30, 2005
    Inventors: Alexander Alanine, Konrad Bleicher, Wolfgang Guba, Wolfgang Haap, Dagmar Kube, Thomas Luebbers, Jean-Marc Plancher, Olivier Roche, Mark Rogers-Evans, Gisbert Schneider, Jochen Zuegge
  • Publication number: 20050119329
    Abstract: This invention relates to new tetronic and tetramic acid derivatives with beta-secretase inhibitory activity of formula I: wherein R1, R2, R3, R4, R5, R5?, R6 and R6? are as defined hereinabove, to processes for their preparation, compositions containing said tetronic and tetramic acid derivatives and their use in the treatment and prevention of diseases modulated by an inhibitor of ?-secretase, such as Alzheimer's disease.
    Type: Application
    Filed: November 22, 2004
    Publication date: June 2, 2005
    Inventors: Thierry Godel, Hans Hilpert, Roland Humm, Mark Rogers-Evans, Didier Rombach, Christoph Stahl, Peter Weiss, Wolfgang Wostl
  • Patent number: 6900227
    Abstract: The present invention relates to compounds of the general formula and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases such as obesity by selective modulation of CB1 receptors.
    Type: Grant
    Filed: July 24, 2003
    Date of Patent: May 31, 2005
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Alexander Alanine, Konrad Bleicher, Wolfgang Guba, Wolfgang Haap, Dagmar Kube, Thomas Luebbers, Jean-Marc Plancher, Olivier Roche, Mark Rogers-Evans, Gisbert Schneider, Jochen Zuegge
  • Publication number: 20050070722
    Abstract: The compound (R)-(1?-benzyl-3-bromo-[1,3?]bipyrrolidinyl-2-one) which is an intermediate for antibacterial vinylpyrrolidinone-cephalosporin derivatives.
    Type: Application
    Filed: August 12, 2004
    Publication date: March 31, 2005
    Inventor: Mark Rogers-Evans
  • Patent number: 6828442
    Abstract: A new process is disclosed for the preparation of bipyrrolidinyl compounds of formula I wherein * signifies an asymmetric center with an (R) or (S) configuration and X represents chlorine, bromine or iodine. The compounds of formula I are important building blocks for the production of useful products in the chemical and in the pharmaceutical industry. In particular they are useful for the production of antibacterial substances such as vinylpyrrolidinone-cephalosporin derivatives.
    Type: Grant
    Filed: February 14, 2003
    Date of Patent: December 7, 2004
    Assignee: Basilea Pharmaceutica AG
    Inventor: Mark Rogers-Evans
  • Publication number: 20040142922
    Abstract: The present invention relates to compounds of the general formula 1
    Type: Application
    Filed: July 24, 2003
    Publication date: July 22, 2004
    Inventors: Alexander Alanine, Konrad Bleicher, Wolfgang Guba, Wolfgang Haap, Dagmar Kube, Thomas Luebbers, Jean-Marc Plancher, Olivier Roche, Mark Rogers-Evans, Gisbert Schneider, Jochen Zuegge
  • Publication number: 20030195364
    Abstract: New process for the preparation of bipyrrolidinyl compounds of formula I wherein * signifies an asymmetric centre with an (R) or (S) configuration and X represents chlorine, bromine or iodine. The compounds of formula I are important building blocks for the production of useful products in the chemical and in the pharmaceutical industry. In particular they are useful for the production of antibacterial substances for example like vinylpyrrolidinone-cephalosporin derivatives.
    Type: Application
    Filed: February 14, 2003
    Publication date: October 16, 2003
    Inventor: Mark Rogers-Evans
  • Publication number: 20030119152
    Abstract: The present invention relates to a new process for the preparation compounds of formula I 1
    Type: Application
    Filed: September 23, 2002
    Publication date: June 26, 2003
    Inventors: Konrad Bleicher, Scott Borthwick, Hans Iding, Mark Rogers-Evans, Stefan Schmid, Han Min Tong, Beat Wirz
  • Patent number: 6420166
    Abstract: The present invention provides a process for the preparation of D-asparagine derivatives of formula I wherein R1 is an amino protecting group and R2 is an alkyl, a substituted alkyl or a group of formula A R3(OCH2CH2)n—  A wherein R3 is hydrogen or an lower alkyl group and n is 1, 2 or 3, which process comprises reacting a compound of formula II wherein R1 and R2 are as defined above, with a protease in an aqueous solution at a pH of 6.0-7.5 and an organic solvent, and subsequently extracting the enantiomeric pure product of formula I. Compounds of formula I can be used as intermediates in the production of antibacterial substances.
    Type: Grant
    Filed: April 12, 2001
    Date of Patent: July 16, 2002
    Assignee: Basolea Pharmaceutica AG
    Inventors: Hans Iding, Mark Rogers-Evans, Beat Wirz
  • Publication number: 20010049127
    Abstract: The present invention provides a process for the preparation of D-asparagine derivatives of formula I 1
    Type: Application
    Filed: April 12, 2001
    Publication date: December 6, 2001
    Inventors: Hans Iding, Mark Rogers-Evans, Beat Wirz
  • Patent number: 6303790
    Abstract: A process is described for preparing certain 4-alkyl- or 4-aryl-pyridine derivatives.
    Type: Grant
    Filed: November 20, 2000
    Date of Patent: October 16, 2001
    Assignee: Hoffman-La Roche Inc.
    Inventors: Hans Hilpert, Fabienne Hoffmann-Emery, Goesta Rimmler, Mark Rogers-Evans, Helmut Werner Stahr, Pius Waldmeier
  • Patent number: 5670640
    Abstract: A process for the manufacture of compounds of formula ##STR1##
    Type: Grant
    Filed: December 9, 1996
    Date of Patent: September 23, 1997
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Mark Rogers-Evans, Paul Spurr